Atara Biotherapeutics (ATRA) Cash & Equivalents (2013 - 2026)

Atara Biotherapeutics (ATRA) has 14 years of Cash & Equivalents data on file, last reported at $8.4 million in Q1 2026.

• Quarterly Cash & Equivalents fell 39.6% year-over-year to $8.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.4 million (down 39.6% YoY) and the FY2025 annual result came in at $8.5 million, down 66.11% from the prior year.
• Cash & Equivalents fell to $8.4 million in Q1 2026, from $8.5 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $101.7 million in Q1 2022 to a low of $5.7 million in Q3 2025.
• A 5-year average of $41.6 million and a median of $35.1 million in 2024 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2023 — Cash & Equivalents dropped 0.5% — and 2025, when it sank 87.64%.
• Tracing ATRA's Cash & Equivalents over 5 years: stood at $92.9 million in 2022, then plunged by 72.2% to $25.8 million in 2023, then dropped by 3.14% to $25.0 million in 2024, then slumped by 66.11% to $8.5 million in 2025, then decreased by 1.44% to $8.4 million in 2026.
• The last three Cash & Equivalents figures came in at $8.4 million (Q1 2026), $8.5 million (Q4 2025), and $5.7 million (Q3 2025), per Business Quant data.